Vonoprazan hydrochloride
Based on 6 publication(s) in Google Scholar
Vonoprazan hydrochloride, a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan hydrochloride inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan hydrochloride is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan hydrochloride can be used for eradication of Helicobacter pylori.
For research use only. We do not sell to patients.
- Purity: 99.41%
- CAS No.: 1957202-44-6
- Formula: C17H17ClFN3O2S
- Molecular Weight:381.85
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Endocrinology Compound Library
HY-L047
-
Antibacterial Compound Library
HY-L049
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Vonoprazan hydrochloride
More- Int J Nanomedicine. 2025 Jun 24:20:8063-8083. [Abstract]
- Eur J Med Chem. 2024 Dec 5:279:116842. [Abstract]
- Drug Dev Res. 2022 Dec 9. [Abstract]
- Drug Metab Dispos. 2016 Oct;44(10):1543-9. [Abstract]
- Toxicol Appl Pharmacol. 2024 May:486:116945. [Abstract]
- Br J Clin Pharmacol. 2019 Jul;85(7):1454-1463. [Abstract]
Biological Activity
IC50: 19 nM (porcine gastric H+,K+-ATPase, at pH 6.5)[2]
Vonoprazan (0.1 nM-10 μM; 30 minutes) exhibits porcine gastric H+, K+-ATPase activity in a concentration-dependent manner[2].
Vonoprazan does not inhibit Na+,K+-ATPase activity, even at concentrations 500 times higher than their IC50 values against gastric H+,K+-ATPase activity[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male 7- or 8-week-old Sprague-Dawley rat[2]
-
Dosage:0.5 mg/kg, 1 mg/kg, 2 mg/kg, 4 mg/kg
-
Administration:Oral administration
-
Result:Inhibited basal gastric acid secretion in a dose-dependent manner.
Chemical Information
-
CAS No. 1957202-44-6
-
Appearance Solid
-
Molecular Weight 381.85
-
Formula C17H17ClFN3O2S
-
Color Off-white to light yellow
-
SMILES
O=S(C1=CC=CN=C1)(N2C=C(CNC)C=C2C3=C(F)C=CC=C3)=O.Cl
-
Synonyms
TAK-438 hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Int J Nanomedicine
Macrophage Membrane-Coated Liposomes Delivering Vonoprazan Disrupt Mitochondrial Oxidative Phosphorylation in Diffuse Large B-Cell Lymphoma. [Abstract]2025 Jun 24:20:8063-8083. PMID: 40626139 -
Eur J Med Chem
2024 Dec 5:279:116842. PMID: 39260319 -
Drug Dev Res
Differential effects of proton pump inhibitors and vonoprazan on vascular endothelial growth factor expression in cancer cells. [Abstract]2022 Dec 9. PMID: 36484282 -
Drug Metab Dispos
Lansoprazole Exacerbates Pemetrexed-Mediated Hematologic Toxicity by Competitive Inhibition of Renal Basolateral Human Organic Anion Transporter 3. [Abstract]2016 Oct;44(10):1543-9. PMID: 27465369 -
Toxicol Appl Pharmacol
In silico and in vitro assessment of drugs potentially causing adverse effects by inhibiting CYP17A1. [Abstract]2024 May:486:116945. PMID: 38688424 -
Br J Clin Pharmacol
Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers. [Abstract]2019 Jul;85(7):1454-1463. PMID: 30845361
Solvent & Solubility
DMSO : 100 mg/mL (261.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Arikawa Y, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem, 2012, 55(9), 4446-4456. [Content Brief]
[2]. Hori Y, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther, 2010, 335(1), 231-238. [Content Brief]
[3]. Sugimoto M, et al. Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan. Front Pharmacol. 2019 Jan 15;9:1560. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6188 mL | 13.0941 mL | 26.1883 mL | 65.4707 mL |
| 5 mM | 0.5238 mL | 2.6188 mL | 5.2377 mL | 13.0941 mL | |
| 10 mM | 0.2619 mL | 1.3094 mL | 2.6188 mL | 6.5471 mL | |
| 15 mM | 0.1746 mL | 0.8729 mL | 1.7459 mL | 4.3647 mL | |
| 20 mM | 0.1309 mL | 0.6547 mL | 1.3094 mL | 3.2735 mL | |
| 25 mM | 0.1048 mL | 0.5238 mL | 1.0475 mL | 2.6188 mL | |
| 30 mM | 0.0873 mL | 0.4365 mL | 0.8729 mL | 2.1824 mL | |
| 40 mM | 0.0655 mL | 0.3274 mL | 0.6547 mL | 1.6368 mL | |
| 50 mM | 0.0524 mL | 0.2619 mL | 0.5238 mL | 1.3094 mL | |
| 60 mM | 0.0436 mL | 0.2182 mL | 0.4365 mL | 1.0912 mL | |
| 80 mM | 0.0327 mL | 0.1637 mL | 0.3274 mL | 0.8184 mL | |
| 100 mM | 0.0262 mL | 0.1309 mL | 0.2619 mL | 0.6547 mL |
Powered by Bioz